<DOC>
	<DOCNO>NCT00523965</DOCNO>
	<brief_summary>Rationale The overall objective trial identify safe effective combination , ( co-administration ) short course treatment treatment VL could easily deploy control programme . The hypothesis combination treatment effective good 5 mg/kg single dose AmBisome reduce risk parasite resistance occur . Safety tolerability combination easily deploy . Objective The specific primary secondary objective follow : Primary objective : To identify short course combination treatment regimen least effective single dose AmBisome 5mg/kg Secondary objective : To compare safety tolerability various treatment measure vital sign , blood biochemistry , ( renal liver function test ) haematology , spontaneous elicit adverse event report Primary Endpoint : The primary efficacy endpoint variable parasitological clearance 2 week start treatment relapse follow clinical sign symptom VL 6 month post treatment . Parasitology carry time follow-up six month post treatment sign symptom VL infection .</brief_summary>
	<brief_title>Combination Therapy Indian Visceral Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>Patients &gt; 5 year old symptom sign kalaazar ( fever , weight loss , splenomegaly ) parasites demonstrated microscopy splenic aspirate smear Pregnant breastfeed woman Individuals seropositive HIV individual serious concurrent infection tuberculosis bacterial pneumonia . Women childbearing age counsel adequate birth control three month miltefosine treatment provide satisfactory method contraception . Granulocyte count &lt; 1,000/mm3 , hemoglobin &lt; 5 g/dL platelet count &lt; 40,000/mm3 Hepatic transaminase total bilirubin great three time normal Serum creatinine &gt; 2.0 mg/dL Prothrombin time &gt; 5 second control Inability subject guardian provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Kala-azar</keyword>
	<keyword>miltefosine</keyword>
	<keyword>liposomal amphotericin B</keyword>
</DOC>